ߺWill Highlight the Platform at Annual SAGES Meeting
CENTER VALLEY, Pa. (March 12, 2025) – ߺCorp., a global medical technology company committed to making people’s lives healthier, safer and more fulfilling, announced today the launch of its first AI-powered clinical decision tool through a strategic partnership with software firm, Ziosoft.
The application integrates advanced imaging analytics and machine learning, empowering surgeons to take ownership of their pre-op planning. This collaboration represents a significant step forward in Olympus's mission to bring innovative, AI-enabled solutions to the healthcare industry to help make clinical workflows more efficient and effective.
The first three applications being launched aim to revolutionize liver, lung, and kidney procedures:
- Thoracic surgery: Transforms 2D CT/MRI images into precise 3D models, aiding in lung cancer and thoracic procedure planning and reducing invasive approaches.
- Liver surgery: Helps general and hepatobiliary surgeons visualize liver anatomy, practice ahead and plan liver-sparing surgeries by visualizing vessels and tumors, helping to improve patient recovery.
- Urologic surgery: Assists in minimally invasive nephrectomies by accurately assessing the size, location and shape of tumors, cysts or other abnormalities.
ߺwill highlight the Ziosoft Revoras platform during the annual Society of Gastrointestinal and Endoscopic Surgeons (SAGES) meeting March 12-15 in Long Beach, Calif.
“ߺhas a proud legacy in medical technology, particularly as a pioneer in endoscopy. We are excited to partner with Ziosoft, which has its own long history of developing AI software to help physicians make more accurate diagnostic and treatment decisions during procedures,” said Darryl Rock, Vice President, Business Unit Leader, Surgical Solutions. “This collaboration represents a significant step forward in Olympus's mission to bring innovative, AI-enabled solutions to the healthcare industry.”
Physicians traditionally utilized flat, 2D images to plan procedures. This new application uses imaging such as CT scans and MRIs to translate static images into dynamic 3D modeling in real time utilizing AI and thousands of radiologic images. The aim is to help physicians make better clinical decisions in sparing as much tissue as possible and improve tumor margins.
The development of 3D procedure modeling can also help educate surgical fellows and help guide newer surgeons through unfamiliar procedures and workflow. This supports Olympus’ commitment to enhancing surgical outcomes with AI-powered clinical decision support applications. It marks the first in a series of surgical innovations aimed at “Seeing the Invisible” designed to make procedures safer, more efficient and consistently successful.
“Ziosoft is committed to improving patient outcomes, and we are pleased to collaborate with ߺto equip clinicians with greater diagnostic capabilities through advanced visualization,” said Rajeev Taitriya, Vice President, Business Development and Marketing, Ziosoft. “By combining our expertise in AI-driven imaging with Olympus’ leadership in minimally invasive treatment solutions, we can help enhance surgical precision and streamline workflows, ultimately improving patient care. With the rise of lung cancer screening, more patients are undergoing complex segmentectomies, which Ziosoft’s REVORAS platform can support by enabling rapid pre-operative planning, allowing thoracic surgeons to make critical surgical decisions in minutes, helping to optimize outcomes and advance the standard of care.”
This surgical planning application will be launched in parallel to the Olympus’ Intelligent Endoscopy Ecosystem, which looks to leverage technologies like AI and integrate hardware, software, services and data to enhance clinical decision-making and streamline workflows in GI.
During the SAGES annual meeting, ߺwill also highlight its surgical portfolio, including their multispecialty imaging platform and the that powers a comprehensive energy solution with applications across numerous specialties such as general surgery, thoracic surgery, urology and gynecology.
ߺwill feature its and CADDIE™ AI System, the first cloud-based AI endoscopy system designed to assist gastroenterologists and colorectal surgeons in detecting suspected colorectal polyps during colonoscopy procedures and localizing disease during surgical procedures
The CADDIE device works by analyzing the endoscopic video of the colon in real-time and using visual markers to alert the endoscopist or surgeon to the potential presence of polyps. The endoscopist or surgeon is responsible for reviewing the CADDIE device’s suspected polyp areas and confirming the presence or absence of a polyp based on their own medical judgment. For more information about Ziosoft or the ߺsurgical portfolio visit the ߺbooth, #749, during SAGES, or visit the .
# # #
About Olympus
At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states.
For more than 100 years, ߺhas pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world.
ߺCorporation of the Americas, a wholly owned subsidiary of ߺCorporation, is headquartered in Center Valley, Pennsylvania, USA, and employs more than 4,500 employees throughout locations in North and South America. For more information, visit
About Ziosoft
Founded in 1998 with offices in Japan and U.S., Ziosoft is a recognized leader in functional CT/MRI 3D visualization and analysis software to benefit physicians, patients and healthcare specialists. With thousands of systems installed in more than 30 countries worldwide and 900 scientific publications, Ziosoft’s true vendor-neutral and multi-modality advanced visualization technology platform is helping patients and clinicians every day, by helping to enable greater diagnostic confidence, lower dose options and precision in treatment planning. As a software-only solution, it is simplified to minimize cost of ownership. For further information on Ziosoft, visit .